The accuracy and convenience of real-time continuous glucose monitoring (CGM) devices have been substantially improved in the past decade, with an accuracy comparable to finger-stick glucose meters. In addition, new advantageous features of CGM devices include a painless one button inserter, smaller (or integrated) transmitters, better connectivity with smartphones, an extended 14-day wear period, no acetaminophen interference, and no need for calibration with a finger-stick glucose meter. Real-time CGM is now the go-to diabetes technology for most people with type 1 diabetes, and acts as a gateway to more advanced diabetes technology. Real-time CGM has become a standard therapy for type 1 diabetes, and a well-proven therapy for type 2 diabetes with multiple daily injections. In the near future, advanced hybrid closed-loop devices with an automated correction bolus will be clinically available, which will be a major breakthrough toward fully automated insulin delivery.